Megadose Methyl-Prednisolone (MDMP) for Autoimmune Hemolytic Anemia

Otoimmün Hemolitik Anemi Tedavisinde Megadoz Metilprednizolon (MDMP)

Şinasi Özsoylu
Fatih University, School of Medicine, Department of Hematology, Ankara, Turkey

To the Editor,

Üsküdar Teke and colleagues originally used 1 mg kg\(^{-1}\) day\(^{-1}\) methylprednisolone (MDMP) for their patient with autoimmune hemolytic anemia without improvement, and after 3 weeks of steroid treatment splenic infarct developed. The patient was splenectomized but the hemolytic anemia again did not improve. Therefore, azathioprine was prescribed [1].

A 36-year-old woman with severe autoimmune hemolytic anemia was sent to me from the Netherlands, who was treated for more than 1.5 years with corticosteroid. Her anemia and hemolysis responded promptly to MDMP administration without disappearance of Coombs positivity [2].

The authors searched for causes of thrombophilia in their patient because of splenic infarct, without evaluation of the fibrinolytic system.

Since the coagulation depends on the dynamic balance between procoagulant and fibrinolytic activities, the later system should also be evaluated in the case of splenic infarct, I believe.

On this occasion, I would like to bring to attention that high homocysteine levels' relation to thrombosis is doubtful, as was previously studied [3].

References

2. Özsoylu Ş, Berencshot H. Megadose prednisolone (MDMP) for a patient with autoimmune hemolytic anemia (AIHA) resistant to conventional corticosteroid administration. (Accepted for publication by TJH)

Reply

We want to thank for the comments of Şinasi ÖZSOYLU, MD. The new diagnosis in primary (idiopathic) autoimmune hemolytic anemia patients is suggested as glucocorticoids (steroids), prednison 1 mg/kg/day or metilprednisolon intravenously. With this dosage it is recommended to continue the treatment until the target hemoglobin value >10 g/dl and hematocrit value >30% are reached and if the target values are not reached within 3 weeks, second step of treatment should be applied [1]. In our case after 3 weeks steroid treatment, both symptomatic splenic infarct development and due to no result of 3 weeks steroid treatment splenectomy is applied simultaneously as a second step treatment. In our case due to splenic infarct development in accordance with etiology trombophilia investigation are
observed [2]. As Dr. Özsoylu has already specified, due to the coagulation being dependant on the dynamic balance between procoagulant and fibrinolytic activity, fibrinolytic system could have been evaluated as well. However, because of the insufficient laboratory conditions, investigation about the fibrinolytic system couldn’t have been done.

Hava Üsküdar Teke¹, Samet Karahan²

¹Eskişehir Osmangazi University, Faculty of Medicine, Department of Hematology, Eskişehir, Turkey
²Kayseri Education and Research Hospital, Department of Internal Medicine, Kayseri, Turkey

References